{
    "code": "02025326",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025326",
    "time": "2016-02-26 03:31:50",
    "許可證字號": "衛署藥輸字第025326號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "110\/01\/19",
    "發證日期": "100\/01\/19",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202532608",
    "中文品名": "可保栓通膜衣錠75毫克\/100毫克",
    "英文品名": "CoPlavix film coated tablets 75mg\/100mg",
    "適應症": "目前正接受Clopidogrel及乙醯水楊酸（ASA）治療以預防粥狀動脈栓塞事件的成人病患可給予CoPlavix。CoPlavix是一種固定劑量的組合藥物，它可作為下列病患之持續治療藥物：1.非ST段上升之急性冠心症（不穩定性心絞痛或非Q波型心肌梗塞），包括接受經皮冠狀動脈介入性治療後放置支架的患者。2.可接受血栓溶解劑治療之ST段上升的急性心肌梗塞病人。",
    "劑型": "116膜衣錠",
    "包裝": "2-1000錠鋁箔盒裝",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "主成分略述": "CLOPIDOGREL HYDROGEN SULFATE, ACETYLSALICYLIC ACID",
    "限制項目": [
        "02輸入"
    ],
    "申請商名稱": "1424601100  賽諾菲股份有限公司",
    "申請商地址": "台北市信義區松仁路3號7樓",
    "主製造廠": {
        "製造廠名稱": "F150008000  SANOFI WINTHROP INDUSTRIE",
        "製造廠廠址": "1,RUE DE LA VIERGE AMBARES ET LAGRAVE 33565 CARBON BLANC CEDEX FRANCE",
        "製造廠公司地址": "",
        "製造廠國別": "FRANCE",
        "製程": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses,put up in measured doses or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "2012600210",
            "成分名稱": "CLOPIDOGREL HYDROGEN SULFATE",
            "含量描述": "(eq to clopidogrel 75mg)",
            "含量": "97.8750000000",
            "單位": "MG"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "2808691110",
            "成分名稱": "ACETYLSALICYLIC ACID",
            "含量描述": "",
            "含量": "100.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Co-Plavix_CCDS v9+10_C_approved-104-07-31.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025326&Seq=006&Type=9"
        },
        {
            "title": "Co-Plavix_CCDS v7+8_C_approved-104-01-19.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025326&Seq=005&Type=9"
        },
        {
            "title": "Co-Plavix_CCDS v5+6_E_approved-2014-02-05.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025326&Seq=004&Type=9"
        },
        {
            "title": "Co-Plavix_CCDS v5+6_C_approved-2014-02-05.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025326&Seq=003&Type=9"
        },
        {
            "title": "Co-Plavix_CCDS v3+4_E_approved-102-11-13.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025326&Seq=002&Type=9"
        },
        {
            "title": "Co-Plavix_CCDS v3+4_C_approved-102-11-13.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025326&Seq=001&Type=9"
        }
    ]
}